Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Disease Areas › Infectious Disease › FIND Joins CARB-X to Support Development of Diagnostics to Combat Antimicrobial Resistance

FIND Joins CARB-X to Support Development of Diagnostics to Combat Antimicrobial Resistance

Feb 26, 2019
|
staff reporter

NEW YORK (360Dx) – The Foundation for Innovative New Diagnostics (FIND) is joining the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) Global Accelerator Network, the organizations announced today.

The CARB-X Global Accelerator Network now includes 10 organizations that provide business, scientific, and technical expertise and services to CARB-X-funded companies to support their antibacterial research projects.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Nov
10
Featured Webinar

IVDR in Light of the COVID Pandemic: The Near Future of In Vitro Diagnostic Testing

Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

What's Popular?

In Infectious Disease

  1. Abbott Q3 Diagnostics Revenues Increase 38 Percent

  2. Danaher Q3 Revenues Up 35 Percent

  3. COVID-19 Testing Plays Into Abbott's Long-Term Diagnostic Strategy

    Premium

  4. BD, CerTest Biotec Get CE-IVD Mark for Combination COVID-19, Influenza, RSV Test on BD Max

  5. Mass Spec Struggles to Demonstrate Utility as Platform for SARS-CoV-2 Dx

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.